Deciphera Pharmaceuticals Culture Company

Mr. Christopher J. Morl, also known as Chris, M.B.A., B.Sc. (Hons) has been the Chief Business Officer of Deciphera Pharmaceuticals, LLC since October 16, 2016. Mr. Morl has more than 25 years of biotech and pharmaceutical industry experience. He served as the Chief Operating Officer of Miragen Therapeutics, Inc. since June 2, 2016 until October 17, 2016 and served as its Chief Business Officer from June 11, 2013 to June 2, 2016. He served in leadership roles for private biotech and multi-national pharmaceutical companies including miRagen Therapeutics, Ambit Biosciences Corporation, Astellas, Inc., Agensys, Inc. and Glaxosmithkline PLC. Prior to joining miRagen, Mr. Morl worked as a consultant advising pre-clinical and clinical stage biotech companies on corporate strategy, business development and financing. Mr. Morl served as Chief Operating Officer at Ambit Biosciences Corporation since 2010 and served as its Chief Business Officer sine joining in 2009. He served as the Vice President of Business Development at Agensys, Inc. Mr. Morl joined Agensys in 2002 from GlaxoSmithKline where since 2001 he led the integration of the GlaxoWellcome and SmithKline Beecham businesses in China Hong Kong. From 1998 to 2001 Mr. Morl served as General Manager of SmithKline Beecham (Tianjin) Ltd. He served as Director of Integration GlaxoSmithKline for China/Hong Kong. Prior to relocating to China in 1998, Mr. Morl served positions with SmithKline Beecham in Business Development, Marketing and R&D for 20 years. He served as a Director of Alethia BioTherapeutics, Inc. since February 10, 2011 until January 9, 2017. Mr. Morl received a BSc in Applied Biology and Pharmacology with Honors in Pharmacology from the University of London (North East London Polytechnic) and an MBA from the Cranfield School of Management (UK).

Dr. Daniel L. Flynn, Ph.D. founded Deciphera Pharmaceuticals, LLC in 2003 and has been its Chief Scientific Officer since April 7, 2014. Dr. Flynn served as the Chief Executive Officer and President of Deciphera Pharmaceuticals LLC from November 2003 to March 2014. He served as Vice President of Chemistry at Neogenesis Pharmaceuticals, Inc. since October 1, 2001. He served as Senior Director of Chemistry at Millennium pharmaceuticals, Inc. from December 1999 to September 2001, where he managed the medicinal chemistry that resulted in the delivery of an anti-obesity drug into human clinical trials. During these years, he developed his interests in chemical genetics and function-blind screening platforms. He also served as Director, Medicinal Chemistry at Amgen, Inc. from October 1998 to November 1999. Dr. Flynn also served as Director of Medicinal Chemistry, Combinatorial Chemistry and Research Fellow at Monsanto Company, G.D. Searle Unit, from 1988 to 1998. He joined Warner-Lambert/Parke Davis pharmaceuticals in Ann Arbor, Michigan, in 1983. In 1988, he moved to Searle Pharmaceuticals in Skokie, IL and later St. Louis, MO. In his ten year period with Searle, he brought over five compounds into preclinical development and advanced 3 drugs into clinical trials, including Xemilofiban and Orbofiban. Dr. Flynn serves as a Member of Scientific Advisory Board of CritiTech, Inc. He served as a Director of Deciphera Pharmaceuticals LLC. Dr. Flynn was the Founder and served as President of The Medicinal & Bioorganic Chemistry Foundation. He is Adjunct Professor of Medicinal Chemistry at the University of Kansas-Lawrence and also serves as the national Chair-Elect for the Division of Medicinal Chemistry of the American Chemical Society. Dr. Flynn received both his Ph.D. in medicinal chemistry and his B.S. in pharmacy from the University of Kansas, and he completed post-doctorate training in synthetic organic chemistry at Indiana University.

Dr. Oliver Rosen, M.D. has been the Chief Medical Officer of Deciphera Pharmaceuticals, LLC since June 30, 2014. Dr. Rosen is responsible for leading the Deciphera Pharmaceuticals, LLC's clinical development strategy and clinical operations which includes a pipeline of cancer therapeutics targeting kinases that play an important role in tumor communication with the surrounding tissue. Prior to joining Deciphera, Dr. Rosen served clinical positions in the oncology field at premier biopharmaceutical companies, including Millennium, Genentech, Amgen, Hoffman La Roche and Merck KGaA. Prior to joining Deciphera, Dr. Rosen served as Vice President of Global and U.S. Medical Affairs at Millennium: The Takeda Oncology Company. Dr. Rosen served senior medical affairs and clinical development roles at Genentech, including Medical Director on the Avastin team. Prior to Genentech, Dr. Rosen served as Associate Director of Medical Affairs at Amgen. Dr. Rosen also served as Clinical Scientist at Hoffman La Roche Ltd. where he was responsible for Phase 3 programs on the Avastin team and Global Project Physician at Merck KGaA. Dr. Rosen received his training in oncology and hematology at the University Hospital Charite in Berlin with research activities focused on hematology and bone marrow transplantation. Prior to his clinical training he participated in a post-doctoral program in Molecular and Cellular Biology at the University of Hamburg. Dr. Rosen obtained his medical degree from the University of Cologne, Germany.

Mr. Thomas Patrick Kelly, also known as Tucker, has been the Chief Financial Officer of Deciphera Pharmaceuticals, LLC since March 2015. Mr. Kelly over 18 years of financial leadership and strategic management experience. He served as Chief Financial Officer of AdvanDx, Inc. Mr. Kelly joined AdvanDx in 2012 and has over 15 years of experience building life sciences and biotechnology companies. He has held positions as a chief financial officer for both public and private companies as well as a life sciences investment banker and a corporate and securities attorney. Prior to joining AdvanDx, Mr. Kelly served as the Chief Financial Officer of deCODE genetics, a leading genetics research company. He was a Principal of Canaccord Adams. Mr. Kelly served as Chief Financial Officer and Senior Vice President of Finance & Corporate Development of Chiesi USA, Inc. (Alternate Name, Cornerstone Therapeutics Inc. and Critical Therapeutics Inc.) from August 20, 2007 to October 31, 2008. He was a Principal of Canaccord Genuity Inc. He joined Adams Harkness (merged into Canaccord Adams in January 2006) as part of the Healthcare Group in 2003 and was responsible for the Emerging Therapeutics banking efforts. He has been life sciences investment banker since 1998. Mr. Kelly served as Vice President of Life Sciences Investment Banking of Robertson Stephens & Co., L.L.C. in both Boston and London. Before his tenure in investment banking, Mr. Kelly served as a Corporate and Securities Attorney of Foley, Hoag & Eliot, LLP. During his career, he has advised public and private life science clients in the United States and in Europe on their corporate finance and capital markets activities on more than 50 financing and advisory transactions. He has an extensive experience in financing and strategic transactions for life science and other growth companies, having completed more than 30 transactions valued in excess of $3 billion. He is also a Massachusetts Bar Association Member. Mr. Kelly received a Bachelor of Science in Foreign Service from Georgetown University and a Juris Doctorate from the University of Chicago Law School.

Peter Lasky serves as the Senior Vice President of Human Resources of Deciphera Pharmaceuticals. Peter started at Deciphera Pharmaceuticals in May of 2018. Peter currently resides in Greater Boston Area.

Eric Haltom serves as the Vice President, Clinical Operations of Deciphera Pharmaceuticals. Eric started at Deciphera Pharmaceuticals in July of 2016. Eric currently resides in Greater Boston Area.

Steve Hoerter serves as the Member Board Of Directors of Deciphera Pharmaceuticals. Steve started at Deciphera Pharmaceuticals in May of 2018. Steve currently resides in Greater Boston Area.

Chris Morl serves as the Chief Business Officer of Deciphera Pharmaceuticals. Chris started at Deciphera Pharmaceuticals in October of 2016. Chris currently resides in the Greater Boston Area.